In this issue:
Bimekizumab vs ustekinumab for moderate-to-severe plaque psoriasis
Respiratory tract infections and interstitial lung disease with IL-12/-23 antagonists
Tuberculosis conversion in psoriasis patients under biologics
Intermittent use of biologic agents for psoriasis
Brodalumab vs ustekinumab: pooled phase III analysis
Guselkumab after failed ustekinumab and/or IL-17
Biologics and apremilast in patients with metabolic conditions
Second-generation antihistamines in chronic spontaneous urticaria
COVID-19, skin diseases and relevant biologics
Please login below to download this issue (PDF)